First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...
The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
The drug leucovorin was touted by the Trump administration in September as a potential treatment for thousands of children with autism. Now, some parents and guardians of children with autism say they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results